Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review

References

• Tan F, Morris PW, Skidgel RA, et al. Sequencing and cloning of human prolylcarboxypeptidase (angiotensinase C). Similarity to both serine carboxypeptidase and prolylendopeptidase families. J Biol Chem. 1993;268(22):16631–16638.
   PubMed Web of Science ®Google Scholar
• Rosenblum JS, Kozarich JW. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol. 2003;7(4):496–504.
   PubMed Web of Science ®Google Scholar
• Skidgel RA, Erdös EG. Cellular carboxypeptidases. Immunol Rev. 1998;161(1):129–141.
   PubMed Web of Science ®Google Scholar
• Kumamoto K, Stewart TA, Johnson AR, et al. Prolylcarboxypeptidase (angiotensinase C) in human lung and cultured cells. J Clin Invest. 1981;67(1):210–215.
   PubMed Web of Science ®Google Scholar
• Yang HYT, Erdös EG, Chiang TS. New enzymatic route for the inactivation of angiotensin. Nature. 1968;218(5148):1224–1226.
   PubMed Web of Science ®Google Scholar
• Jeong JK, Diano S. Prolyl carboxypeptidase mRNA expression in the mouse brain. Brain Res. 2014;1542:85–92.
   PubMed Web of Science ®Google Scholar
• Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem. 2002;277(20):17962–17969.
   PubMed Web of Science ®Google Scholar
• Miller JJ, Changaris DG, Levy RS. Angiotensin carboxypeptidase activity in urine from normal subjects and patients with kidney damage. Life Sci. 1991;48(16):1529–1535.
   PubMed Web of Science ®Google Scholar
• Odya CE, Marinkovic DV, Hammon KJ, et al. Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. J Biol Chem. 1978;253(17):5927–5931.
   PubMed Web of Science ®Google Scholar
• Abeywickrema PD, Patel SB, Byrne NJ, et al. Expression, purification and crystallization of human prolylcarboxypeptidase. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010;66(6):702–705.
   PubMedGoogle Scholar
• Soisson SM, Patel SB, Abeywickrema PD, et al. Structural definition and substrate specificity of the S28 protease family: the crystal structure of human prolylcarboxypeptidase. BMC Struct Biol. 2010;10:16.
   PubMed Web of Science ®Google Scholar
• Shariat-Madar B, Taherian M, Shariat-Madar Z. On the mechanism of action of prolylcarboxypeptidase. In: Atiq M, editor. Recent advances in cardiovascular risk factors. New York: InTech; 2012. p. 255–274.
   Google Scholar
• Jeong JK, Diano S. Prolyl carboxypeptidase and its inhibitors in metabolism. Trends Endocrinol Metab. 2013;24(2):61–67.
   PubMed Web of Science ®Google Scholar
• Sabrina D. New aspects of melanocortin signaling: a role for PRCP in α-MSH degradation. Front Neuroendocrinol. 2011;32(1):70–83.
   PubMed Web of Science ®Google Scholar
• Chajkowski-Scarry S, Rimoldi JM. Discovery and development of prolylcarboxypeptidase inhibitors for cardiometabolic disorders. Annu Rep Med Chem. 2013;48:91–103.
   Web of Science ®Google Scholar
• Mountjoy KG. Pro-opiomelanocortin (POMC) neurones, POMC-derived peptides, melanocortin receptors and obesity: how understanding of this system has changed over the last decade. J Neuroendocrinol. 2015;27(6):406–418.
   PubMed Web of Science ®Google Scholar
• Cowley MA, Smart JL, Rubinstein M, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature. 2001;411:480–484.
   PubMed Web of Science ®Google Scholar
• D’Agostino G, Diano S. alpha-Melanocyte stimulating hormone: production and degradation. J Mol Med. 2010;88(12):1195–1201.
   PubMed Web of Science ®Google Scholar
• Wallingford N, Perroud B, Gao Q, et al. Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents. J Clin Invest. 2009;119(8):2291–2303.
   PubMed Web of Science ®Google Scholar
• Jeong JK, Szabo G, Kelly K, et al. Prolyl carboxypeptidase regulates energy expenditure and the thyroid axis. Endocrinology. 2012;153(2):683–689.
   PubMed Web of Science ®Google Scholar
• Jeong JK, Szabo G, Raso GM, et al. Deletion of prolyl carboxypeptidase attenuates the metabolic effects of diet-induced obesity. Am J Physiol Endocrinol Metab. 2012;302(12):E1502–E1510.
   PubMed Web of Science ®Google Scholar
• Jeong JK, Kim JD, Diano S. Ghrelin regulates hypothalamic prolyl carboxypeptidase expression in mice. Mol Metab. 2013;2(1):23–30.
   PubMed Web of Science ®Google Scholar
• Xu S, Lind L, Zhao L, et al. Plasma prolylcarboxypeptidase (angiotensinase C) is increased in obesity and diabetes mellitus and related to cardiovascular dysfunction. Clin Chem. 2012;58(7):1110–1115.
   PubMed Web of Science ®Google Scholar
• Chiao H, Foster S, Thomas R, et al. Alpha-melanocyte-stimulating hormone reduces endotoxin-induced liver inflammation. J Clin Invest. 1996;97:2038–2044.
   PubMed Web of Science ®Google Scholar
• Shariat-Madar B, Kolte D, Verlangieri A, et al. Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment. Diabetes Metab Syndr Obes. 2010;3:67–78.
   PubMedGoogle Scholar
• Palmiter RD. Reduced levels of neurotransmitter-degrading enzyme PRCP promote a lean phenotype. J Clin Invest. 2009;119(8):2130–2133.
   PubMed Web of Science ®Google Scholar
• Sampaio WO, Souza Dos Santos RA, Faria-Silva R, et al. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension. 2007;49(1):185–192.
   PubMed Web of Science ®Google Scholar
• Simões E Silva AC, Silveira KD, Ferreira AJ, et al. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol. 2013;169(3):477–492.
   PubMed Web of Science ®Google Scholar
• Adams GN, LaRusch GA, Stavrou E, et al. Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood. 2011;117:3929–3937.
   PubMed Web of Science ®Google Scholar
• Maier C, Schadock I, Haber PK, et al. Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II. J Mol Med. 2017;95(5):473–486.
   PubMed Web of Science ®Google Scholar
• Wang L, Feng Y, Zhang Y, et al. Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia. Am J Obstet Gynecol. 2006;195(1):162–171.
   PubMed Web of Science ®Google Scholar
• Watson B Jr, Nowak NJ, Myracle AD, et al. The human angiotensinase C gene (HUMPCP) maps to 11q14 within 700 kb of D11S901: a candidate gene for essential hypertension. Genomics. 1997;44(3):365–367.
   PubMed Web of Science ®Google Scholar
• McCarthy JJ, Meyer J, Moliterno DJ, et al. Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. Hum Genet. 2003;114(1):87–98.
   PubMed Web of Science ®Google Scholar
• Dielis AWJH, Smid M, Spronk HMH, et al. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems. Hypertension. 2005;46:1236–1242.
   PubMed Web of Science ®Google Scholar
• Shariat-Madar Z, Mahdi F, Schmaier AH. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood. 2004;103(12):4554–4561.
   PubMed Web of Science ®Google Scholar
• Chajkowski SM, Mallela J, Watson DE, et al. Highly selective hydrolysis of kinins by recombinant prolylcarboxypeptidase. Biochem Biophys Res Commun. 2011;405(3):338–343.
   PubMed Web of Science ®Google Scholar
• Wang J, Matafonov A, Madkhali H, et al. Prolylcarboxypeptidase independently activates plasma prekallikrein (Fletcher factor). Curr Mol Med. 2014;14(9):1173–1185.
   PubMed Web of Science ®Google Scholar
• Ngo M-L, Mahdi F, Kolte D, et al. Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation. J Inflammation. 2009;6:3.
   Google Scholar
• Mallela J, Yang J, Shariat-Madar Z. Prolylcarboxypeptidase: a cardioprotective enzyme. Int J Biochem Cell Biol. 2009;41(3):477–481.
   PubMed Web of Science ®Google Scholar
• Adams GN, Stavrou EX, Fang C, et al. Prolylcarboxypeptidase promotes angiogenesis and vascular repair. Blood. 2013;122(8):1522–1531.
   PubMed Web of Science ®Google Scholar
• Kumamoto K, Stewart TA, Johnson AR, et al. Prolylcarboxypeptidase (angiotensinase C) in human lung and cultured cells. J Clin Invest. 1981;67:210–215.
   PubMed Web of Science ®Google Scholar
• Shariat-Madar Z, Mahdi F, Warnock M, et al. Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood. 2006;108(1):192–199.
   PubMed Web of Science ®Google Scholar
• Su JB. Different cross-talk sites between the renin−angiotensin and the kallikrein−kinin systems. J Renin-Angiotensin-Aldosterone Syst. 2014;15(4):319–328.
   PubMed Web of Science ®Google Scholar
• Schmaier AH. The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am J Physiol Regul Integr Comp Physiol. 2003;285(1):R1–R13.
   PubMed Web of Science ®Google Scholar
• Zhu L, Carretero OA, Liao TD, et al. Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells. Hypertension. 2010;56(3):384–390.
   PubMed Web of Science ®Google Scholar
• Grobe N, Leiva O, Morris M, et al. Loss of prolyl carboxypeptidase in two-kidney, one-clip Goldblatt hypertensive mice. PLoS One. 10(2):e0117899.
   PubMed Web of Science ®Google Scholar
• Waumans Y, Baerts L, Kehoe K, et al. The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Front Immunol. 2015;6:387.
   PubMed Web of Science ®Google Scholar
• Zhao X, Southwick K, Cardasis HL, et al. Peptidomic profiling of human cerebrospinal fluid identifies YPRPIHPA as a novel substrate for prolylcarboxypeptidase. Proteomics. 2010;10(15):2882–2886.
   PubMed Web of Science ®Google Scholar
• Duan L, Motchoulski N, Danzer B, et al. Prolylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells. J Biol Chem. 2011;286(4):2864–2876.
   PubMed Web of Science ®Google Scholar
• Javerzat S, Franco M, Herbert J, et al. Correlating global gene regulation to angiogenesis in the developing chick extra-embryonic vascular system. PLoS One. 2009;4(11):e7856.
   PubMed Web of Science ®Google Scholar
• Castan-Laurell I, Dray C, Attané C, et al. Apelin, diabetes, and obesity. Endocrine. 2011;40(1):1–9.
   PubMed Web of Science ®Google Scholar
• Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251(2):471–476.
   PubMed Web of Science ®Google Scholar
• Pitkin SL, Maguire JJ, Bonner TI, et al. International union of basic and clinical pharmacology. LXXIV Apelin Receptor Nomenclature Distribution Pharmacology Function. Pharmacol Rev. 2010;62(3):331–342.
   PubMed Web of Science ®Google Scholar
• Aydin S, Eren MN, Sahin İ, et al. The role of apelins in the physiology of the heart. Protein Pept Lett. 2014;21(1):2–9.
   PubMed Web of Science ®Google Scholar
• Kehoe K, Van Elzen R, Verkerk R, et al. Prolyl carboxypeptidase purified from human placenta: its characterization and identification as an apelin-cleaving enzyme. Biochim Biophys Acta. 2016;1864(11):1481–1488.
   PubMed Web of Science ®Google Scholar
• Bertrand C, Valet P, Castan-Laurell I. Apelin and energy metabolism. Front Physiol. 2015;6(115):1–5.
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc. Kenilworth, NJ, USA, is known as Merck Sharp & Dohme (MSD) outside of the United States and Canada.
   Google Scholar
• Zhou C, Garcia-Calvo M, Pinto S, et al. Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity. J Med Chem. 2010;53(19):7251–7263.
   PubMed Web of Science ®Google Scholar
• For a related series, see, Wu Z, Yang C, Xiong Y, et al. Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine. Bioorg Med Chem Lett. 2012;22(4):1774–1778.
   PubMed Web of Science ®Google Scholar
• Tolerability refers for any unintended effects from the drug and can include appetite suppression and weight loss. The exact biochemical cause is often unknown and these effects can confound anti-obesity study results.
   Google Scholar
• Shen HC, Ding F-X, Zhou C, et al. Discovery of benzimidazole pyrrolidinyl amides as prolylcarboxypeptidase inhibitors. Bioorg Med Chem Lett. 2011;21(5):1299–1305.
   PubMed Web of Science ®Google Scholar
• Graham TH, Shen HC, Liu W, et al. The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors. Bioorg Med Chem Lett. 2012;22(1):658–665.
   PubMed Web of Science ®Google Scholar
• Wu Z, Yang C, Graham TH, et al. Discovery of aminoheterocycles as potent and brain penetrant prolylcarboxypeptidase inhibitors. Bioorg Med Chem Lett. 2012;22(4):1727–1730.
   PubMed Web of Science ®Google Scholar
• The fluorescence substrate was (1S)-1-carboxy-5-[(2,4-dinitrophenyl)amino]pentyl-N-[(7-methoxy-2-oxo-2H-chromen-4-yl)acetyl] -L-alanyl-L-prolinate.
   Google Scholar
• Merck & Co., Inc., Kenilworth, NJ, USA. Novel spiropiperidine prolylcarboxypeptidase inhibitors. WO2011137024. (2011).
   Google Scholar
• Shen HC, Ding F-X, Jiang J, et al. Discovery of benzodihydroisofurans as novel, potent, bioavailable and brain-penetrant prolylcarboxypeptidase inhibitors. Bioorg Med Chem Lett. 2012;22(4):1550–1556.
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc., Kenilworth, NJ, USA. Prolylcarboxypeptidase inhibitors. WO 2011137012. (2011).
   Google Scholar
• Graham TH, Shu M, Verras A, et al. Pyrazoles as non-classical bioisosteres in prolylcarboxypeptidase (PrCP) inhibitors. Bioorg Med Chem Lett. 2014;24(7):1657–1660.
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc., Kenilworth, NJ, USA. Novel prolylcarboxypeptidase inhibitors. WO2011143057. (2011).
   Google Scholar
• Merck & Co., Inc., Kenilworth, NJ, USA. Novel prolylcarboxypeptidase inhibitors. WO2011146354. (2011).
   Google Scholar
• Merck & Co., Inc., Kenilworth, NJ, USA. Novel prolylcarboxypeptidase inhibitors. WO2011156246. (2011).
   Google Scholar
• Merck & Co., Inc., Kenilworth, NJ, USA. Novel prolylcarboxypeptidase inhibitors. WO2011146300. (2011).
   Google Scholar
• Debenham JS, Graham TH, Verras A, et al. Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors. Bioorg Med Chem Lett. 2013;23(23):6228–6233.
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc., Kenilworth, NJ, USA. Novel prolylcarboxypeptidase inhibitors. WO2011156220. (2011).
   Google Scholar
• Graham TH, Liu W, Verras A, et al. A new class of prolylcarboxypeptidase inhibitors. Part 1: Discovery and evaluation. Bioorg Med Chem Lett. 2012;22(8):2811–2817.
   PubMed Web of Science ®Google Scholar
• Graham TH, Liu W, Verras A, et al. A new class of prolylcarboxypeptidase inhibitors. Part 2: Aminocyclopentanes. Bioorg Med Chem Lett. 2012;22(8):2818–2822.
   PubMed Web of Science ®Google Scholar
• The University of Mississippi, University, MS, USA. Novel selective inhibitors of prolylcarboxypeptidase. WO2012075287. (2012).
   Google Scholar
• Rabey FM, Gadepalli RSVS, Diano S, et al. Influence of a novel inhibitor (UM8190) of prolylcarboxypeptidase (PRCP) on appetite and thrombosis. Curr Med Chem. 2012;19(24):4194–4206.
   PubMed Web of Science ®Google Scholar
• Yale University, New Haven, CT, USA and the Regents of the University of California, Oakland, CA, USA. Detection and use of prolylcarboxypeptidase. WO2005115446. (2005).
   Google Scholar
• Free drug concentrations in the brain were not reported.
   Google Scholar
• Others have also suggested that additional regulating peptides could be substrates of PrCP. For additional details, refer to ref. 6.
   Google Scholar
• Kehoe K, Brouns R, Verkerk R, et al. Prolyl carboxypeptidase activity decline correlates with severity and short-term outcome in acute ischemic stroke. Neurochem Res. 2015;40(1):81–88.
   PubMed Web of Science ®Google Scholar